Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 928 results
Filters: Author is Bosch, Ronald J  [Clear All Filters]
Found 928 results.


Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Gandhi RT, Bosch RJ, Aga E, et al. "No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy." J. Infect. Dis.. 2010;201(2):293-6.
Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. "The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era." Antivir. Ther. (Lond.). 2009;14(4):543-9.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Smurzynski M, Collier AC, Koletar SL, et al. "AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics." HIV Clin Trials. 2008;9(4):269-82.
Robertson KR, Smurzynski M, Parsons TD, et al. "The prevalence and incidence of neurocognitive impairment in the HAART era." AIDS. 2007;21(14):1915-21.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Volberding P, Demeter L, Bosch RJ, et al. "Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment." AIDS. 2009;23(15):1987-95.
Schacker TW, Bosch RJ, Bennett K, et al. "Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV." J. Acquir. Immune Defic. Syndr.. 2010;54(1):59-62.
Riddler SA, Aga E, Bosch RJ, et al. "Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy." J. Infect. Dis.. 2016;213(4):556-60.
Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ. "Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment." HIV Clin Trials. 2013;14(2):61-7.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.
Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. "Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2007;44(3):268-77.